SPOTLIGHT -
Ms Kuntz is the assistant managing editor of Psychiatric Times.
TEV-‘749 Demonstrates No Incidence Of Postinjection Delirium/Sedation Syndrome in New Data
Check out new positive efficacy, safety, and tolerability results from the phase 3 SOLARIS trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia.
Deutetrabenazine Shows Long Term Efficacy and Safety in Patients with Tardive Dyskinesia
A new analysis from a 3-year open-label extension study revealed that treatment with deutetrabenazine was associated with long term improvement of symptoms of tardive dyskinesia.
A Case of Comorbid PTSD and Alcohol Use Disorder
Enter your email to check out this complicated case!
New Study Shows High Doses of Amphetamine Increase Risk for Developing Psychosis
A new study of adult emergency department admissions found that individuals taking high doses of amphetamine—like Adderall—have a 5-fold increased risk for developing psychosis or mania.
The Anniversary of 9/11 Research Roundup
Learn more about the latest research related to 9/11 trauma and other psychiatric comorbidities.
First Digital Treatment for Generalized Anxiety Disorder Cleared by the FDA
DaylightRx becomes the very first FDA-cleared digital treatment for generalized anxiety disorder.
New Study Initiated to Evaluate Use of Deep Brain Stimulation for Treatment-Resistant Depression
Abbott has initiated the TRANSCEND study to evaluate the use of deep brain stimulation to manage treatment-resistant depression.
Presenting Our September Theme: Forensic Psychiatry
Write to us now to be part of our series on forensic psychiatry!
Preventing Overdose Deaths: How to Reduce Social Stigma and Barriers to Care
Tomorrow, August 31, is Overdose Awareness Day. What can you be doing to help prevent overdose deaths?
Major Depressive Disorder Research Roundup: August 29, 2024
What is new in research on major depressive disorder?
New Positive Results for NBI-1117568 in Adults With Schizophrenia
The first investigational, oral, muscarinic M4 selective agonist in development for the treatment of schizophrenia sees positive phase 2 results in the lowest tested dose.
VLS-01 for Treatment-Resistant Depression: Positive Phase1B Results
New phase 1b results of VLS-01, an oral transmucosal film formulation of DMT, show ‘psychologically meaningful’ improvement for patients with treatment-resistant depression.
5 Key Take-Aways About PTSD Treatment: A Closer Look at MDMA
At least 1 in 2 people experience trauma at some point in their life, and a subset of those individuals will develop PTSD.
Presenting Our August Theme: The Psychiatric Pipeline and Treatment Updates
Write to us now to be part of our series on treatment updates this month.
FDA Approves Erzofri for the Treatment of Schizophrenia and Schizoaffective Disorder
The US Food and Drug Administration has approved Erzofri, a paliperidone palmitate extended-release injectable suspension for the treatment of adults with schizophrenia and schizoaffective disorder.
sNDA Submitted: Spravato as Monotherapy for Treatment-Resistant Depression
A supplemental New Drug Application has been submitted to the FDA seeking approval of esketamine (Spravato) CIII nasal spray as a monotherapy for adults with treatment-resistant depression.
OX124 for Opioid Overdose Reversal Receives FDA Complete Response Letter
The FDA has issued a complete response letter to Orexo for OX124, a high-dose naloxone nasal spray for opioid overdose reversal.
Alcohol Use Disorder Research Roundup: July 11, 2024
What is new in research on alcohol use disorder?
Eating Disorders in LGBTQ+ Patients: Recommendations and Clinical Pearls
How are eating disorders different in LGBTQ+ patients compared with cisgender heterosexual patients? How can you best help manage eating disorders in this patient population?
Which Antidepressant Causes the Least Amount of Weight Gain?
New research found that among 8 first-line antidepressants, bupropion was associated with the least weight gain most consistently.
What It Means to Be a Humanitarian Celebrating the Work of H. Steven Moffic, MD
Psychiatric Times asked H. Steven Moffic, MD, to share his thoughts on humanitarianism and psychiatry.
Alzheimer Disease Treatment Donanemab Receives FDA Approval
Kisunla (donanemab-azbt) is now approved by the FDA for adults with early symptomatic Alzheimer disease.
Presenting Our July Theme: Schizophrenia
Write to us now to be part of our series focused on schizophrenia this month.
The Potential of Ketamine: Public Workshop and New Research Explores Uses
While ketamine is a not approved for the treatment of depression or chronic pain, clinicians have shown increased interest in using it for these conditions. An FDA workshop is exploring its potential.
Approved sNDA: Wakix for Treatment of Excessive Daytime Sleepiness in Youth With Narcolepsy
The FDA has approved its supplemental New Drug Application for Wakix tablets for the treatment of excessive daytime sleepiness in pediatric patients aged 6 years and older with narcolepsy.
First Nontobacco Flavored E-Cigarette Products Authorized by the FDA
The FDA has authorized the marketing of 4 menthol-flavored e-cigarette products in the United States through the premarket tobacco product application pathway.
Phase 2 Study Initiated: ALTO-101 for Cognitive Impairment With Schizophrenia
ALTO-101 has previously been shown to positively impact cognition in schizophrenia.
A Brief Cannabis Cessation Protocol to Increase Patient Motivation
Cannabis withdrawal syndrome impacts approximately half of those who use it regularly. How can you help patients cease cannabis use?
How to Safely and Effectively Taper Benzodiazepines
Review tapering challenges and strategies for benzodiazepines in this Special Report article.
Lumateperone as an Adjunctive Therapy to Antidepressants: More Positive Results
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints, according to new study.